Skip to main content

Table 4 Results of Sensitivity Analyses

From: Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis

 1:1 Propensity Score MatchingOn-Treatment Approach
3-Month
 Composite of recurrent venous thromboembolism or major bleeding1.10 (0.82–1.46)1.10 (0.83–1.45)
 Recurrent venous thromboembolism1.08 (0.78–1.50)1.11 (0.81–1.52)
 Major bleeding1.28 (0.73–2.25)1.17 (0.69–1.98)
 Intracranial hemorrhage1.04 (0.15–7.37)0.65 (0.12–3.47)
 Gastrointestinal bleeding1.11 (0.56–2.19)1.08 (0.55–2.13)
 Genitourinary bleeding1.39 (0.31–6.21)1.05 (0.29–3.75)
6-Month
 Composite of recurrent venous thromboembolism or major bleeding1.00 (0.767–1.31)1.05 (0.81–1.37)
 Recurrent venous thromboembolism1.04 (0.76–1.41)1.12 (0.83–1.53)
 Major bleeding1.02 (0.62–1.69)1.01 (0.62–1.66)
 Intracranial hemorrhage0.70 (0.12–4.20)0.65 (0.12–3.47)
 Gastrointestinal bleeding0.80 (0.43–1.47)0.94 (0.50–1.78)
 Genitourinary bleeding1.39 (0.31–6.21)0.85 (0.25–2.84)
12-Month
 Composite of recurrent venous thromboembolism or major bleeding0.98 (0.76–1.25)1.04 (0.80–1.34)
 Recurrent venous thromboembolism1.00 (0.75–1.34)1.10 (0.82–1.47)
 Major bleeding0.99 (0.64–1.5)0.98 (0.61–1.57)
 Intracranial hemorrhage0.94 (0.29–3.10)0.82 (0.21–3.30)
 Gastrointestinal bleeding0.84 (0.47–1.48)0.88 (0.47–1.65)
 Genitourinary bleeding1.34 (0.36–5.00)1.03 (0.33–3.24)